EXV-802 and EXV-801 for agitation in people with Alzheimer's disease dementia
Tests EXV-802 and EXV-801 against placebo for agitation in Alzheimer's disease dementia.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Key facts
- Where
- Bennington, Brooklyn, Flowood, Independence, Indianapolis, Murrieta, New York, and Portland, United StatesSee the 8 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
Source: NCT07284472, who can take part
Where in United States
- The Memory ClinicBennington, United StatesTaking people
- Integrative Clinical TrialsBrooklyn, United StatesTaking people
- Precise Research CentersFlowood, United StatesTaking people
- Insight Clinical TrialsIndependence, United StatesTaking people
- Josephson Wallack Munshower Neurology, PCIndianapolis, United StatesTaking people
- Esperanza ClinicalMurrieta, United StatesTaking people
- Manhattan Behavioral MedicineNew York, United StatesTaking people
- Oregon Health Science UniversityPortland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exciva GmbH
- Trial code
- NCT07284472EU 2024-517388-22-00
- Record updated
- 6 November 2026
- Original description
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.Read full original descriptionShow less
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Inclusion: The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair; A previously established diagnosis of AD dementia; The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization; The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation; Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.
Exclusion: The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia; The participant has symptoms of agitation that are not secondary to AD dementia; The participant has a history of uncontrolled seizures or a history of epilepsy; The participant has a major medical illness or unstable medical condition.